Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 30/04/2018 |
| Rapid review completed | 07/06/2018 |
| Rapid Review outcome | Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013. |
The HSE has approved reimbursement following confidential price negotiations December 2018.